Lifeward Ltd. 8-K

What Happened Lifeward Ltd. filed an 8-K on March 20, 2026 reporting that, on March 17, 2026, it received a notice from Nasdaq that the company no longer meets the audit committee requirement of Nasdaq Listing Rule 5605(c)(2)(A) after director Hadar Levy resigned, leaving the audit committee with two members. The company says it is reviewing options to regain compliance within the cure period set by Nasdaq.

Key Details

• Notice received: March 17, 2026; 8-K filed March 20, 2026.
• Cause: Resignation of Hadar Levy reduced the audit committee to two members (Nasdaq requires at least three).
• Cure period: Company must regain compliance by the earlier of its next annual shareholders’ meeting or February 24, 2027; if the next annual meeting is held before August 24, 2026, compliance must be evidenced by August 24, 2026.
• Immediate effect: The notice does not immediately affect listing; ordinary shares will continue trading on The Nasdaq Capital Market under the symbol "LFWD." The company said there is no assurance it will regain compliance in the cure period.

Why It Matters This is a corporate governance compliance issue that Nasdaq deems material because failure to restore a compliant audit committee could lead to further Nasdaq action, including potential delisting if not cured. For investors, the filing signals a governance gap that the company must address within specified deadlines; however, trading of LFWD shares remains unaffected for now.